MBX Biosciences (MBX) vs Perrigo (PRGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MBX Biosciences (MBX) has outperformed Perrigo (PRGO) over the past year, gaining 83.0% versus a gain of 26.1%. MBX Biosciences is the larger company by market cap ($2.46 billion vs $2.21 billion), about 1.1 times the size. Perrigo pays a dividend yielding 7.28%, while MBX Biosciences does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | PRGO |
|---|---|---|
| Share price | $49.55 | $15.94 |
| Market cap | $2.46B | $2.21B |
| 1-day change | -7.23% | -0.62% |
| YTD return | +57.10% | +14.51% |
| 1-year return | +82.98% | +26.11% |
| 5-year return | — | -57.81% |
| Forward P/E | — | 6.94 |
| EPS (TTM) | $-3.03 | $-12.47 |
| Dividend yield | 0.00% | 7.28% |
| Annual dividend | $0.00 | $1.16 |
| Revenue (latest FY) | — | $4.25B |
| Revenue growth (YoY) | — | -2.75% |
| Net income (latest FY) | $-87.00M | $-1.43B |
| Gross margin | — | 35.14% |
| Operating margin | — | -26.39% |
| Net margin | — | -33.51% |
| 52-week high | $72.64 | $17.07 |
| 52-week low | $26.14 | $9.23 |
| Distance from 52-week high | -31.79% | -6.62% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +91.91% | +12.92% |
| Average volume | 532.80K | 2.54M |
| Shares outstanding | 49.66M | 138.80M |
| Employees | 63 | 8,100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed PRGO by 56.9 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.28% vs 0.00%).
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
MBX vs PRGO FAQ
Which is bigger, MBX Biosciences or Perrigo?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.46B compared with $2.21B for Perrigo (PRGO).
Which stock has performed better over the past year, MBX or PRGO?
MBX returned +82.98% over the past 12 months, compared with +26.11% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, MBX Biosciences or Perrigo?
Perrigo pays a dividend yielding 7.28%, while MBX Biosciences does not currently pay a regular dividend.
Are MBX Biosciences and Perrigo in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.